Article
Envision Pharma Group
ctDNA Breakthroughs in Mesothelioma Care
Clips
Summary
Exploring immunotherapy and ctDNA innovation in mesothelioma, where molecular monitoring may redefine early cancer detection and treatment.
In this insightful episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs sits down with Dr. Mark Sausen, Labcorp's Head of Technology and Innovation, to break down a cutting-edge Phase II clinical trial exploring perioperative immunotherapy for resectable diffuse pleural mesothelioma, a rare and aggressive cancer.
Hear firsthand how the introduction of immune checkpoint blockade and an ultrasensitive tumor-informed ctDNA platform offers new hope for tracking and treating patients when imaging falls short. Dr. Sausen shares the technological breakthroughs behind molecular residual disease detection, the impact of ctDNA on progression-free survival, and practical challenges in implementing these assays across multicenter studies.
Whether you’re a clinician, researcher, or patient advocate, discover how molecular monitoring is changing the game for mesothelioma and rare cancers alike.
Related Topics
You May Also Like
Envision Pharma Group
Article
Rajat Thawani, Neha Agrawal, Nicholas F Taflin, Adel Kardosh, Emerson Y Chen
Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer
Article
Jonathan H. Cheng, Justin W. Tiulim, Sheng Zhou, Anthony El-Khoueiry and Jorge Nieva
Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials
Article
S.E. Abdullah, E. Oflazoglu, J.C. Soria, M.M. Dar
New Realities of Phase I Clinical Trials in the Era of
Article
Louis Everest, BSc; Monica Shah, BSc; Kelvin K.W. Chan, MD, MSc, PhD
Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale
Article
Alyson Haslam, PhD; Vinay Prasad, MD, MPH